In My Opinion
Sumanta K. Pal, MD: Let's Get More Patients With Rare Tumors Into Clinical Trials
Sumanta K. Pal, MD, of City of Hope, talks about the need for investigators across the country to enroll their patients with rare tumors in clinical trials. He describes a trial he is leading for papi...
Karim Fizazi, MD, PhD: We Need to Find a Way to Make Cancer Drugs Affordable
Karim Fizazi, MD, PhD, of Gustave Roussy, urges governments, insurers, and pharmaceutical companies to work together in order to find a way to make anticancer drugs affordable and accessible for all p...
A. Oliver Sartor, MD, on Issues in Immunotherapy
A. Oliver Sartor, MD, of Tulane University, speaks anecdotally about immunotherapy for prostate cancer and shares his experiences in speaking to patients with late-stage disease about the knowns, unkn...
Owen A. O’Connor, MD, PhD, on Issues in Immunotherapy
Owen A. O'Connor, MD, PhD, of Columbia University Medical Center, shares his perspective on immunotherapy for patients with late-stage cancer in the context of a clinical trial setting and recent Righ...
Andrew D. Seidman, MD, on Embracing Computer-Assisted Decision-Making
Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, discusses the benefits of decision support tools, especially for the oncologist who treats a variety of cancers in his or her practice...
Allen S. Lichter, MD, and Mark J. Ratain, MD, on Better Dosing, Lower Cost: Improving Cancer Care and Value
Allen S. Lichter, MD, Board Chair of the Value in Cancer Care Consortium, and Mark J. Ratain, MD, of the University of Chicago, discuss the benefits—and challenges—of lowering dosages in the face of m...
